Trial document




This trial has been registered retrospectively.
drksid header

  DRKS00006046

Trial Description

start of 1:1-Block title

Title

Therapy monitoring of omalizumab in children and adolescents with severe allergic asthma

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

[---]*

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

The monoclonal anti-IgE antibody omalizumab is used as add-on therapy for improved asthma control in children and adolescents with severe persistent allergic bronchial asthma. The aim of the study was to examine the effectiveness of omalizumab and to demonstrate the hitherto unavailable possibilities for treatment monitoring by means of a bed-side immunoassay. In the prospective longitudinal study patients aged 6 to 18 years with severe persistent allergic asthma received add-on treatment with omalizumab. Besides the parameters of general physical examination, recordings of exacerbation rate, asthma control and lung function (FEV1), total IgE concentrations in serum were determined after 6 and 12 months; free IgE was measured using immunoassays.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

Therapeutic antibodies have become increasingly important in the treatment of diseases with inflammatory background. Omalizumab has been used successfully for years in Germany as add-on therapy for improved asthma control in children over 6 years of age with severe persistent allergic bronchial asthma. Omalizumab is a monoclonal anti-IgE antibody that binds to circulating IgE molecules and suppresses the expression of the high-affinity IgE receptor on mast cells, basophilic granulocytes and other immune effector cells. The dosage and dose frequency are guided by the total serum IgE and the patient’s weight prior to the onset of treatment. The largely schematic administration leaves little room for individualised therapy. Until now, only the reduction in asthma symptoms and improved asthma control have been important for assessing the course of the disease in patients on Omalizumab therapy. Thus, routine diagnostic tests to measure free serum IgE together with a thourough clinical examination would allow an individualized therapy minimizing costs and patients’ medicinal burden.
The aim of the study was to examine the effectiveness of omalizumab and to demonstrate the hitherto unavailable possibilities for treatment monitoring by means of a bed-side immunoassay. In the prospective longitudinal study patients aged 6 to 18 years with severe persistent allergic asthma received add-on treatment with omalizumab. Besides the parameters of general physical examination, recordings of exacerbation rate, asthma control and lung function (FEV1), total IgE concentrations in serum were determined after 6 and 12 months; free IgE was measured using immunoassays.

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00006046
  •   2014/04/01
  •   [---]*
  •   yes
  •   Approved
  •   80/11, Ethik-Kommission des Fachbereichs Medizin der Justus-Liebig-Universität Gießen
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  • [---]*
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   J45.0 -  Predominantly allergic asthma
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   open-descriptive-not interventional-oberservational study.
    In a prospective longitudinal study patients aged 6 to 18 years with severe persistent allergic asthma received add-on treatment with omalizumab. Bedsides the parameters of general physical examination, recordings of exacerbation rate, asthma control and lung function (FEV1), total IgE concentrations in serum and free IgE were measured with special immunassays.
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Non-interventional
  •   Observational study
  •   Single arm study
  •   Open (masking not used)
  •   [---]*
  •   Uncontrolled/Single arm
  •   Treatment
  •   Single (group)
  •   N/A
  •   No
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Total IgE and free IgE concentrations in serum were determined after 6 and 12 months (Sandwich-Immunassay)

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

Recordings of exacerbation rate, asthma control and lung function (FEV1) determined after 6 and 12 months start the omalizumab therapy

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • [---]*
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   Actual
  •   2011/05/02
  •   15
  •   Monocenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   6   Years
  •   18   Years
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

severe allergic asthma
> 6 years of age
<18 years of age
informed consent of the patients and their parents

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

no severe allergic asthma
< 6 years of age
> 18 years of age

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Universitätsklinikum Gießen und Marburg
    • Rudolf-Buchheim-Str. 8
    • 35392  Giessen
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Universitätsklinikum Gießen und Marburg
    • Mr.  PD Dr.med.  Jens-Oliver  Steiß 
    • Rudolf-Buchheim-Str. 8
    • 35392  Giessen
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Universitätsklinikum Gießen und Marburg
    • Mr.  PD Dr.med.  Jens-Oliver  Steiß 
    • Rudolf-Buchheim-Str. 8
    • 35392  Giessen
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Zentrum für Kinderheilkunde und JugendmedizinUniversitätsklinikum Gießen und Marburg GmbHPädiatrische Pneumologie udn Allergologie
    • Mr.  PD D.med.  Jens-Oliver  Steiß 
    • Feulgenstraße 12
    • 35385  Gießen
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting ongoing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.